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Background: RBFOX1 is an important splicing factor regulating developmental and tissue-specific alternative
splicing in heart, muscle, and neuronal tissues. Constitutional genetic defects in RBFOX1 are implicated in multiple
medical conditions.
Results: We identified 14 copy number variants (CNV) involving RBFOX1 from 2,124 consecutive pediatric patients
referred for chromosomal microarray analysis (CMA), including 13 intragenic deletions and a single intragenic
duplication. The clinical significances of the intragenic deletions of RBFOX1 were evaluated.
Conclusions: Our data strongly supports the associations of intragenic deletions of RBFOX1 with a diversity of
neurodevelopmental and neuropsychiatric disorders, and possibly other clinical features.
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Developmental delayBackground
RBFOX1 [RNA binding protein, fox-1 homolog (C. elegans)],
located at human chromosome 16p13.3, is one of the three
member in Fox gene family encoding splicing factors [1,2].
It is specifically expressed in heart, muscle and neuronal
tissues, regulating developmental and tissue-specific
alternative splicing by binding with (U)GCAUG se-
quence in introns flanking alternative exons of its target
genes [1,3-6]. RBFOX1 was initially identified as a binding
partner of the brain-specific protein ATXN2, causing
spinocerebellar ataxia 2 (SCA2) when the CAG repeats in
this gene are expanded. Since then, constitutional genetic
defects in RBFOX1 are implicated in multiple medical
conditions including mental retardation and epilepsy
[7], bipolar schizoaffective disorder [8], attention-deficit
hyperactivity disorder (ADHD) [9], autism [10-13], hand
osteoarthritis [14], congenital heart defects [15], obesity
and diabetes [16,17], Intracranial arachnoid cysts [18],
and primary biliary cirrhosis [19].Correspondence: lab-zhaoweiwei@kingmed.com.cn
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In this report, we evaluated the clinical significances of
the intragenic deletions/duplication of RBFOX1 in 12 out
of 14 patients who carry the genomic imbalances. Fourteen
copy number variants (CNV) involving RBFOX1, including
13 intragenic deletions and a single intragenic duplica-
tion, were identified in this cohort (Figure 1; Table 1),
representing ~0.66% (14/2,124) of the patients analyzed in
this study. There are no other clinically relevant CNVs in
their genomes except in Patient 6 who carries an additional
178 kb deletion of 1p31.3 involving NF1A besides the
intragenic deletion of RBFOX. Of the 13 deletions, 4 of
them (in patients 1, 3, 5, and 6) involve exons while the
remaining deletions involve only introns. The intragenic
duplication in Patient 6 involves exons 4 and 5 of RBFOX1.
The deletions/duplications were confirmed by qPCR
methods (data not shown). The deletion in Patient 5
was maternally inherited while both deletions in Patient 6
occurred de novo. The inheritance patterns of the dele-
tions/duplication could not be determined in remaining
patients due to unavailability of DNA samples from either
one parent in Patient 8 or both parents in other patients.
By comparing breakpoints of the 14 intragenic deletions/
duplication within the group and with the CNVs involvingis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Genomic overview of the intragenic deletions (patients 1–13) and duplication of RBFOX1 (patient 14) in this study.
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variation/), multiple hot spots involving the generation of
CNVs within RBFOX1 were observed, such as the proximal
breakpoints of the CNVs in Patients 7, 8, and 11, and both
proximal and distal breakpoints of the CNVs in Patients 9
and 10 (Figure 1; Table 1). In addition, G-banding analysis
showed negative results for all 14 patients while a patho-
genic mutation in ZEB2 and a pathogenic mutation in
F8 were identified in Patient 1 and Patient 9 respectively.
Of the 14 patients containing intragenic deletions/
duplication of RBFOX1 (Tables 1 and 2), two of them were
excluded for further analysis of the genotype-phenotypeTable 1 CNVs involving RBFOX1gene on chromosome 16
Case Start* (bp) Stop*(bp) Size (bp) Del/Dup A
1 6,296,453 6,317,524 21,071 Del
2 6,398,588 6,417,167 18,579 Del
3 6,500,668 6,737,047 236,379 Del
4 6,567,938 6,609,613 41,675 Del
5 6,597,626 6,759,803 162,177 Del
6 6,752,063 7,577,445 825,382 Del
7 6,781,978 6,948,525 166,547 Del
8 6,829,209 6,904,158 74,949 Del
9 6,860,713 7,018,893 158,180 Del
10 6,866,819 7,011,349 144,530 Del
11 6,883,111 6,912,449 29,338 Del
12 7,079,544 7,133,209 53,665 Del
13 7,132,809 7,170,657 37,848 Del
14 6,689,120 7,062,757 373,637 Dup
Notes: *The genomic coordinates of these CNVs were based on the human genomecorrelations, including Patient 1 who was diagnosed with
Mowat-Wilson syndrome both phenotypically and geno-
typically, and Patient 14, the single case with an intragenic
duplication of RBFOX1 accompanied with multiple
congenital anomalies. Although both Patients 6 and 9
contain additional genomic abnormalities in addition to the
intragenic deletions of RBFOX1, these two cases were
included for further analysis since the clinical significance
of the 178 kb deletion of 1p31.3 (61,318,736-61,496,706) in-
volving NFIA in Patient 6 has not been defined yet and the
mild hemophilia A in Patient 9 is assumed not to interfere
the phenotypic effects of the RBFOX1 deletion. Recurrentffected exon(s) Inheritance and comments
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annotation of hg18 build; Del deletion, Dup duplication, NT not tested.
Table 2 Clinical findings in patients with intragenic deletions/duplication in this study
Cases Sex Dysmorphism Neurological problems GDD/Autism/speech delay Other organ abnormalities/disorders
1 F None None GDD Hypotonia, feeding problems, eczema,
bilateral renal reflux and dilatation,
episodes of fussiness and gassiness,
chronic constipation, a diagnosis of
Mowat-Wilson syndrome
2 M Macrocephaly None GDD, Autism Hypothyroid at birth, history of
lactic acidosis
3 M None Epilepsy None Gastroesophageal reflux, voiding
dysfunction and nocturnal enuresis,
and adenoid hypertrophy
4 M Severe microcephaly Perinatal hypoxic ischemic
encephalopathy with resultant
severe cystic encephalomalacia,
focal epilepsy, cerebral palsy,
asymmetric spasticity
GDD, especially speech delay None
5 F None None None Bicuspid aortic valve with aortic
dilation, anomalous superior left
pulmonary venous return
6 M Macrocephaly None Severe GDD Hypotonia, kyphosis
7 M None Encephalopathy Alexia, dyslexia Short stature
8 M None Epilepsy Mild developmental delay,
speech delay
Hypospadias
9 M Macrocephaly Poorly developed corpus callosum Severe GDD Hearing impairment, hypernatremia
and renal insufficiency, a diagnosis of
mild hemophilia A
10 F None None None Hypotonia, tracheal malasia,
11 F Plagiocephaly and
infantile torticolli
Epilepsy, abnormal EEG with a slow
background and temporal spikes,
and staring spells
GDD, especially speech delay Hearing impairment
12 F None Epilepsy Intellectual disability,
aggressive behavior
None
13 M Severe microcephaly
and micrognathia
Epilepsy, ventriculomegaly None Paralyzed vocal cords, bilateral
equinovarus, contractures of knees
and hips bilaterally
14* M None None NA Atrioventricular canal, transposition of
the great arteries, pulmonary valve
atresia, supraventricular tachycardia,
and congenital absence of spleen
Notes: *-newborn; M male, F female, GDD global developmental delay, EEG electroencephalogram, NA not applicable.
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deletions of RBFOX1 include global developmental delay
(GDD) (7/12), epilepsy (6/12), macrocephaly or microceph-
aly (6/12), renal problems (4/12), such as single kidney,
renal insufficiency, hypospadias, voiding dysfunction and
nocturnal enuresis, bone and muscle problems (4/12), such
as hemivertebrae, kyphosis, equinovarus, contractures of
knees and hips, hypotonia (2/12), and hearing impairment
(2/12). Some isolated findings were also observed, including
autism, paralyzed vocal cords, tracheomalacia, gastroesoph-
ageal reflux, complex congenital heart defect, short stature,
type II diabetes, adenoid hypertrophy, hypothyroidism,
lactic acidosis, and hypernatremia (Table 2).
We believe the intragenic deletions of RBFOX1 identified
in these patients are risk factors for a wide spectrum of
neurodevelopmental disorders and other clinical features.1. Comparing with healthy groups, the 0.61% (13/2,124)
detection rate of intragenic deletions of RBFOX1 in our
study is significantly higher than the rate observed in
control populations, such as the 0.1% (2/1854) in Itsara’s
report [20] and the 0.2% (4/2026) in Shaikh’s report [21].
2. Genetic defects including point mutations or intragenic
deletions of RBFOX1 were independently reported to be as-
sociated with a variety of clinical conditions [7,9-11,14-19].
Majority of the clinical findings in the 12 patients in our co-
hort, such as GDD, seizures, and other neurodevelopmental
and neuropsychiatric disorders, are consistent with those
reported cases who carried genetic defects in RBFOX1
[7-11,22]. For example, a recent study identified exonic
deletions of the RBFOX1gene in 5 of the 1,408 European
patients with idiopathic generalized epilepsy (IGE), but in
none of the 2,256 population controls [22]. Davis LK et al.
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with autism and developmental hemiparesis [23]. Bone
and muscle problems present in multiple cases in this study
were also observed in a report [14]. 3. The intragenic dele-
tions of RBFOX1 in patient 6 occurred de novo, providing
additional support about its pathological relevance to severe
GDD, macrocephaly, hypotonia, and kyphosis in this
patient. 4. More importantly, functional studies on RBFOX1
strongly support the etiological roles of RBFOX1 for
neurodevelopmental disorders [10,24,25]. For example,
almost identical to the knockout mice (Rbfox1-/-) with
central nervous system (CNS)-specific deletion of Rbfox1,
mice with heterozygous deletion (Rbfox1+/-) showed a dra-
matically increased susceptibility to induced seizures [24].
The loss of Rbfox1 was found to cause an increase in ex-
citability of the neuronal population of the dentate gyrus
resulting from an altered synaptic function. Martin et al.
reported a 160 kb cryptic deletion of RBFOX1 within the
breakpoint involved in a translocation between the short
arms of chromosomes 15 and 16 in a female with autism,
epilepsy, and GDD [10]. Accompanied with this heterozy-
gous deletion, reduced mRNA expression in the individual’s
lymphocytes was showed, demonstrating the functional
consequence of the RBFOX1 deletion in multiple tissues.
In a mouse model of Facioscapulohumeral muscular dys-
trophy (FSHD), Pistoni et al. recently showed that reducing
Rbfox1 expression inhibits muscle differentiation [25].
There are several weaknesses in this study. 1. Ascertain-
ment bias exists in our cohort since many of the patients
were referred for CMA analysis because of unexplained
neurodevelopmental and neuropsychiatric presentations.
2. Intragenic deletions of RBFOX1 were observed in
some individuals with apparently normal phenotypes
although incomplete penetrance of RBFOX1 defects
exist [20,21] (http://projects.tcag.ca/variation/). 3. Most
of the intragenic deletions of RBFOX1 in our patients
affected only introns or the noncoding exons although
point mutations or intragenic deletions of RBFOX1
were considered pathogenic in majority of the previous
studies [7,9-11,14-19]. 4. The inheritance pattern(s) of
the intragenic deletions of RBFOX1 in this study could
not be determined in majority of them due to unavailability
of parental samples and Patient 5 who inherited the
deletion from her mother, the only determined inheritance
of the deletion in this study, showed a different phenotype
compared with her mother [15] although variable expres-
sivity might exist.
In conclusion, the current study strongly supports the
associations of intragenic deletions of RBFOX1 with a
diversity of neurodevelopmental and neuropsychiatric
disorders, and possibly other clinical features. Our data
expend the spectrums of both the genomic abnormalities
of RBFOX1 and phenotypic presentations associated with
mutated RBFOX.Material and methods
The DNA samples used for the current study came from
2,124 consecutive pediatric patients referred for chromo-
somal microarray analysis (CMA) in our laboratory. Each
child had one or more of the following clinical findings
at the time of referral: intellectual disability, develop-
mental delay, multiple congenital anomalies (MCA),
autism spectrum disorders (ASD), dysmorphism, seizures,
learning disabilities or speech delays. Informed consents of
all patients analyzed in this study were obtained from the
parents and the institutional review board of KingMed
Genome Diagnostic Laboratory approved this study protocol.
The CMAplatform used in this study is the Agilent Human
Genome Microarray Kit 244K which contains about
244,000 probes across human genome including 186 probes
encompassing RBFOX1 (Agilent Technologies, Santa
Clara, CA). All CMA tests were performed and analyzed
following protocols described previously [26]. The genomic
coordinates of these CNVs in this study were based on the
human genome annotation of hg18 build. For confirmation
of the abnormal CMA results, quantitative real time
PCR (qPCR) methods were performed using three
different sets of primers targeting to the deleted regions of
RBFOX1 as described previously [27]. The qPCR method
was also applied to test the 5 available parental samples
(2 couples and 1 single parent) for determination of the
inheritance pattern of the genomic abnormalities in their
respective children (Table 1). In addition, all the 14 indi-
viduals were previously tested by standard chromosome
analysis (G-banding) with negative results and some of
them were evaluated by specific genetic tests.
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